ContraFect Corp
(NASDAQ:CFRX)
$0.0696
0.0001[0.14%]
At close: Feb 3
$0.0703
0.0007[1.01%]
After Hours: 7:57PM EDT
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520

ContraFect Stock (NASDAQ:CFRX), Quotes and News Summary

ContraFect Stock (NASDAQ: CFRX) stock price, news, charts, stock research, profile.

Loading...
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520
InvestorsObserver - 4 days ago
InvestorPlace - Jan 27, 2023, 9:17AM
InvestorsObserver - Jan 24, 2023, 10:15AM
InvestorsObserver - Jan 6, 2023, 11:47AM
InvestorsObserver - Jan 4, 2023, 12:10PM
Seeking Alpha - Dec 13, 2022, 8:41AM
Sector: Health Care.Industry: Biotechnology
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-23
REV
Q3 2022Est.ActualSurprise
EPS-0.230-0.430 -0.2000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy ContraFect (CFRX) stock?

A

You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ContraFect's (CFRX) competitors?

Q

What is the target price for ContraFect (CFRX) stock?

A

The latest price target for ContraFect (NASDAQ: CFRX) was reported by Maxim Group on Thursday, July 14, 2022. The analyst firm set a price target for 0.00 expecting CFRX to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ContraFect (CFRX)?

A

The stock price for ContraFect (NASDAQ: CFRX) is $0.0696 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does ContraFect (CFRX) pay a dividend?

A

There are no upcoming dividends for ContraFect.

Q

When is ContraFect (NASDAQ:CFRX) reporting earnings?

A

ContraFect’s Q4 earnings are confirmed for Thursday, March 23, 2023.

Q

Is ContraFect (CFRX) going to split?

A

There is no upcoming split for ContraFect.

Q

What sector and industry does ContraFect (CFRX) operate in?

A

ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

ContraFect Stock (NASDAQ:CFRX), Quotes and News Summary

ContraFect Stock (NASDAQ: CFRX) stock price, news, charts, stock research, profile.

Loading...
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520
InvestorsObserver - 4 days ago
InvestorPlace - Jan 27, 2023, 9:17AM
InvestorsObserver - Jan 24, 2023, 10:15AM
InvestorsObserver - Jan 6, 2023, 11:47AM
InvestorsObserver - Jan 4, 2023, 12:10PM
Seeking Alpha - Dec 13, 2022, 8:41AM
Sector: Health Care.Industry: Biotechnology
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-23
REV
Q3 2022Est.ActualSurprise
EPS-0.230-0.430 -0.2000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy ContraFect (CFRX) stock?

A

You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ContraFect's (CFRX) competitors?

Q

What is the target price for ContraFect (CFRX) stock?

A

The latest price target for ContraFect (NASDAQ: CFRX) was reported by Maxim Group on Thursday, July 14, 2022. The analyst firm set a price target for 0.00 expecting CFRX to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ContraFect (CFRX)?

A

The stock price for ContraFect (NASDAQ: CFRX) is $0.0696 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does ContraFect (CFRX) pay a dividend?

A

There are no upcoming dividends for ContraFect.

Q

When is ContraFect (NASDAQ:CFRX) reporting earnings?

A

ContraFect’s Q4 earnings are confirmed for Thursday, March 23, 2023.

Q

Is ContraFect (CFRX) going to split?

A

There is no upcoming split for ContraFect.

Q

What sector and industry does ContraFect (CFRX) operate in?

A

ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

ContraFect Stock (NASDAQ:CFRX), Quotes and News Summary

ContraFect Stock (NASDAQ: CFRX) stock price, news, charts, stock research, profile.

Loading...
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520
InvestorsObserver - 4 days ago
InvestorPlace - Jan 27, 2023, 9:17AM
InvestorsObserver - Jan 24, 2023, 10:15AM
InvestorsObserver - Jan 6, 2023, 11:47AM
InvestorsObserver - Jan 4, 2023, 12:10PM
Seeking Alpha - Dec 13, 2022, 8:41AM
Sector: Health Care.Industry: Biotechnology
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-23
REV
Q3 2022Est.ActualSurprise
EPS-0.230-0.430 -0.2000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy ContraFect (CFRX) stock?

A

You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ContraFect's (CFRX) competitors?

Q

What is the target price for ContraFect (CFRX) stock?

A

The latest price target for ContraFect (NASDAQ: CFRX) was reported by Maxim Group on Thursday, July 14, 2022. The analyst firm set a price target for 0.00 expecting CFRX to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ContraFect (CFRX)?

A

The stock price for ContraFect (NASDAQ: CFRX) is $0.0696 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does ContraFect (CFRX) pay a dividend?

A

There are no upcoming dividends for ContraFect.

Q

When is ContraFect (NASDAQ:CFRX) reporting earnings?

A

ContraFect’s Q4 earnings are confirmed for Thursday, March 23, 2023.

Q

Is ContraFect (CFRX) going to split?

A

There is no upcoming split for ContraFect.

Q

What sector and industry does ContraFect (CFRX) operate in?

A

ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

ContraFect Stock (NASDAQ:CFRX), Quotes and News Summary

ContraFect Stock (NASDAQ: CFRX) stock price, news, charts, stock research, profile.

Loading...
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520
InvestorsObserver - 4 days ago
InvestorPlace - Jan 27, 2023, 9:17AM
InvestorsObserver - Jan 24, 2023, 10:15AM
InvestorsObserver - Jan 6, 2023, 11:47AM
InvestorsObserver - Jan 4, 2023, 12:10PM
Seeking Alpha - Dec 13, 2022, 8:41AM
Sector: Health Care.Industry: Biotechnology
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-23
REV
Q3 2022Est.ActualSurprise
EPS-0.230-0.430 -0.2000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy ContraFect (CFRX) stock?

A

You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ContraFect's (CFRX) competitors?

Q

What is the target price for ContraFect (CFRX) stock?

A

The latest price target for ContraFect (NASDAQ: CFRX) was reported by Maxim Group on Thursday, July 14, 2022. The analyst firm set a price target for 0.00 expecting CFRX to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ContraFect (CFRX)?

A

The stock price for ContraFect (NASDAQ: CFRX) is $0.0696 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does ContraFect (CFRX) pay a dividend?

A

There are no upcoming dividends for ContraFect.

Q

When is ContraFect (NASDAQ:CFRX) reporting earnings?

A

ContraFect’s Q4 earnings are confirmed for Thursday, March 23, 2023.

Q

Is ContraFect (CFRX) going to split?

A

There is no upcoming split for ContraFect.

Q

What sector and industry does ContraFect (CFRX) operate in?

A

ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

ContraFect Stock (NASDAQ:CFRX), Quotes and News Summary

ContraFect Stock (NASDAQ: CFRX) stock price, news, charts, stock research, profile.

Loading...
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520
InvestorsObserver - 4 days ago
InvestorPlace - Jan 27, 2023, 9:17AM
InvestorsObserver - Jan 24, 2023, 10:15AM
InvestorsObserver - Jan 6, 2023, 11:47AM
InvestorsObserver - Jan 4, 2023, 12:10PM
Seeking Alpha - Dec 13, 2022, 8:41AM
Sector: Health Care.Industry: Biotechnology
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-23
REV
Q3 2022Est.ActualSurprise
EPS-0.230-0.430 -0.2000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy ContraFect (CFRX) stock?

A

You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ContraFect's (CFRX) competitors?

Q

What is the target price for ContraFect (CFRX) stock?

A

The latest price target for ContraFect (NASDAQ: CFRX) was reported by Maxim Group on Thursday, July 14, 2022. The analyst firm set a price target for 0.00 expecting CFRX to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ContraFect (CFRX)?

A

The stock price for ContraFect (NASDAQ: CFRX) is $0.0696 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does ContraFect (CFRX) pay a dividend?

A

There are no upcoming dividends for ContraFect.

Q

When is ContraFect (NASDAQ:CFRX) reporting earnings?

A

ContraFect’s Q4 earnings are confirmed for Thursday, March 23, 2023.

Q

Is ContraFect (CFRX) going to split?

A

There is no upcoming split for ContraFect.

Q

What sector and industry does ContraFect (CFRX) operate in?

A

ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

ContraFect Stock (NASDAQ:CFRX), Quotes and News Summary

ContraFect Stock (NASDAQ: CFRX) stock price, news, charts, stock research, profile.

Loading...
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520
InvestorsObserver - 4 days ago
InvestorPlace - Jan 27, 2023, 9:17AM
InvestorsObserver - Jan 24, 2023, 10:15AM
InvestorsObserver - Jan 6, 2023, 11:47AM
InvestorsObserver - Jan 4, 2023, 12:10PM
Seeking Alpha - Dec 13, 2022, 8:41AM
Sector: Health Care.Industry: Biotechnology
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-23
REV
Q3 2022Est.ActualSurprise
EPS-0.230-0.430 -0.2000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy ContraFect (CFRX) stock?

A

You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ContraFect's (CFRX) competitors?

Q

What is the target price for ContraFect (CFRX) stock?

A

The latest price target for ContraFect (NASDAQ: CFRX) was reported by Maxim Group on Thursday, July 14, 2022. The analyst firm set a price target for 0.00 expecting CFRX to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ContraFect (CFRX)?

A

The stock price for ContraFect (NASDAQ: CFRX) is $0.0696 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does ContraFect (CFRX) pay a dividend?

A

There are no upcoming dividends for ContraFect.

Q

When is ContraFect (NASDAQ:CFRX) reporting earnings?

A

ContraFect’s Q4 earnings are confirmed for Thursday, March 23, 2023.

Q

Is ContraFect (CFRX) going to split?

A

There is no upcoming split for ContraFect.

Q

What sector and industry does ContraFect (CFRX) operate in?

A

ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

ContraFect Stock (NASDAQ:CFRX), Quotes and News Summary

ContraFect Stock (NASDAQ: CFRX) stock price, news, charts, stock research, profile.

Loading...
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520
InvestorsObserver - 4 days ago
InvestorPlace - Jan 27, 2023, 9:17AM
InvestorsObserver - Jan 24, 2023, 10:15AM
InvestorsObserver - Jan 6, 2023, 11:47AM
InvestorsObserver - Jan 4, 2023, 12:10PM
Seeking Alpha - Dec 13, 2022, 8:41AM
Sector: Health Care.Industry: Biotechnology
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-23
REV
Q3 2022Est.ActualSurprise
EPS-0.230-0.430 -0.2000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy ContraFect (CFRX) stock?

A

You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ContraFect's (CFRX) competitors?

Q

What is the target price for ContraFect (CFRX) stock?

A

The latest price target for ContraFect (NASDAQ: CFRX) was reported by Maxim Group on Thursday, July 14, 2022. The analyst firm set a price target for 0.00 expecting CFRX to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ContraFect (CFRX)?

A

The stock price for ContraFect (NASDAQ: CFRX) is $0.0696 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does ContraFect (CFRX) pay a dividend?

A

There are no upcoming dividends for ContraFect.

Q

When is ContraFect (NASDAQ:CFRX) reporting earnings?

A

ContraFect’s Q4 earnings are confirmed for Thursday, March 23, 2023.

Q

Is ContraFect (CFRX) going to split?

A

There is no upcoming split for ContraFect.

Q

What sector and industry does ContraFect (CFRX) operate in?

A

ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

ContraFect Stock (NASDAQ:CFRX), Quotes and News Summary

ContraFect Stock (NASDAQ: CFRX) stock price, news, charts, stock research, profile.

Loading...
Day Range0.068 - 0.07252 Wk Range0.059 - 4.540Open / Close0.070 / 0.070Float / Outstanding43.638M / 43.683M
Vol / Avg.8.881M / 9.799MMkt Cap3.040MP/E-50d Avg. Price0.110
Div / Yield (Forward)- / -%Payout Ratio-Total Float43.638MEPS-1.520
InvestorsObserver - 4 days ago
InvestorPlace - Jan 27, 2023, 9:17AM
InvestorsObserver - Jan 24, 2023, 10:15AM
InvestorsObserver - Jan 6, 2023, 11:47AM
InvestorsObserver - Jan 4, 2023, 12:10PM
Seeking Alpha - Dec 13, 2022, 8:41AM
Sector: Health Care.Industry: Biotechnology
ContraFect Corp is a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lysin exebacase has a targeted spectrum of activity, meaning that it kills specific species of Staphylococci or closely related bacteria. Its IND candidate, CF-370, targets resistant gram-negative bacteria including Pseudomonas aeruginosa (P. aeruginosa). Its advanced clinical candidate, exebacase, is an investigational novel lysin that targets Staphylococcus aureus (Staph aureus), including methicillin-resistant (MRSA) strains, which causes serious infections such as bacteremia, pneumonia and osteomyelitis.

Earnings

see more
Q4 2022Est.ActualSurprise
EPS
(EXPECTED)2023-03-23
REV
Q3 2022Est.ActualSurprise
EPS-0.230-0.430 -0.2000
REV0

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target
Q

How do I buy ContraFect (CFRX) stock?

A

You can purchase shares of ContraFect (NASDAQ: CFRX) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are ContraFect's (CFRX) competitors?

Q

What is the target price for ContraFect (CFRX) stock?

A

The latest price target for ContraFect (NASDAQ: CFRX) was reported by Maxim Group on Thursday, July 14, 2022. The analyst firm set a price target for 0.00 expecting CFRX to fall to within 12 months (a possible -100.00% downside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for ContraFect (CFRX)?

A

The stock price for ContraFect (NASDAQ: CFRX) is $0.0696 last updated February 3, 2023 at 9:00 PM UTC.

Q

Does ContraFect (CFRX) pay a dividend?

A

There are no upcoming dividends for ContraFect.

Q

When is ContraFect (NASDAQ:CFRX) reporting earnings?

A

ContraFect’s Q4 earnings are confirmed for Thursday, March 23, 2023.

Q

Is ContraFect (CFRX) going to split?

A

There is no upcoming split for ContraFect.

Q

What sector and industry does ContraFect (CFRX) operate in?

A

ContraFect is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.